前几天偶然发现，大名鼎鼎的 SPSS 被更大名鼎鼎的 IBM 收购了，时间是 2009 年，目前的SPSS软件是IBM SPSS 20.0。前者是举世闻名的统计软件，后者是全球知名的 IBM 公司。要论影响力， IBM 的影响力远在 SPSS 之上，因为 SPSS 只在专业领域享有声誉，而 IBM 呢？恐怕全世界没有一个人能够离得开 IBM ，我们每天上网浏览的网站后台数据库，在 IBM PC 兼容机基础上发展出来的微机，几乎都是 IBM 的功劳。 对 IBM 我是有内心崇拜情节的，一家公司能够引起我发自内心的尊敬是不容易的。根源在于我是最早的电脑发烧友之一，当时所用的电脑就是 IBM PC 兼容机，随着其他厂商激烈的竞争，进入 20 世纪 90 年代，有一段时间 IBM 日子并不好过，于是发明了“电子商务”，现在其实并没有多少人知道“电子商务”一词是 IBM 公司发明的，当然再后来， 1998 年我创办了全国第一个电子商务专业——国际贸易（电子商务），绝对具有前瞻性，虽然现在我的研究方向不在该领域，但时常关注电子商务的发展。 至于笔记本电脑，更不能忘记 THINKPAD 了，红点鼠标是 IBM 首创，据说这个小东西有 17 项专利， IBM THINKPAD 一度成为笔记本电脑的代名词。 IBM 笔记本绝对是一台可靠的工作电脑，不花哨，但绝对值得信赖。后来随着激烈的市场竞争， IBM 调整战略，将 PC 业务卖给联想，为此我到现在内心仍然有小小的不快，但仍然坚持用着联想的 THINKPAD 电脑，但实在找不到用 IBM 笔记本的那种感觉。 几年前， IBM 公司由于工作人员的疏忽，将价值 1800 元的笔记本电脑外置刻录机价格错标为 1 元，等数小时发现时网上已经被人订购了上万台，你猜怎么着？ IBM 恢复了原来的价格，但对已经订购刻录机的兑现订单，一元一台！你说这样的公司怎么可能不让人发自内心的尊重。 至于说到科技创新， IBM 绝对是该领域最伟大的公司。在 IBM 公司，创新早已不是什么口号。相比我国上上下下，天天宣传的东东简直是冷笑话。 中国有这样的公司吗？应该有，可以有，但是现在没有，希望将来 50 年、 100 年之后能有。 忽然想起一个笑话，大意是上帝问美国足球队、英国足球队、日本足球队何时能够拿世界冠军，回答都有几十年的时间，有人问上帝，中国足球何时能拿世界冠军，结果上帝哭了。 看到球迷整天看欧洲足球，巴西足球，就是不看中国足球，以前不能理解。现在我理解了，正和我崇拜 IBM 公司一样。 2012.7.4 俞立平 于宁波
今年1月29日，上海医药宣布，董事会决议出资12.41亿元继续收购China Health System Ltd.（CHS）约34.76%股权，从而完成对CHS9家股东100％的股权收购。该交易总对价达35.69亿元，为中国医药分销市场改革以来交易金额最大的并购交易案。2010年底，通过两次收购，上海医药已获得CHS现有6家股东合计持有的CHS约65.24%控制性股权，合计支付对价23.28亿元。CHS实质性资产为中信医药实业有限公司。本次收购将使上海医药得以建立以北京地区为中心的华北地区医药分销网络资源，真正实现总部设在上海、拥有全国性分销网络的全产业链的大型医药产业集团。 北京地区是中国最重要的卫生资源集聚中心，是我国仅次于上海的第二大医药市场。而中信医药名列2009年度中国医药商业企业第18位，主要业务集中在北京市场，市场占有率排名当地第三。本次收购完成后，上海医药将实现以华东、华南、华北为重点区域的全国性医药分销网络格局。在上药收购中信时，上海医药董事长吕明方曾表示，中信医药是北京地区排名前三的医药分销企业，上药对其实施收购后，有望在分销业务上在北京市场坐二望一，直接威胁华润在北京市场的地位。分析人士表示：“上药并购中信的主要原因是对华润南下的一次有力反击。上药拿下中信医药后，业务得以冲出华东地区，开始向华北地区扩散。” 上海医药半年报数据显示，CHS上半年净利润8915万元，同比增长30%。据此计算，CHS2010年的净利润约为1.4亿元，上海医药给出的收购价PE值约为25倍。对此，上海医药董事长吕明方在中报业绩说明会上表示，“举报信确实有。事实上，在这次收购之前与之后，竞争对手公司给出的收购价PE值都有比中信医药高的。”而业内分析人士表示，“这个溢价在业内并不常见，但若说流失国有资产不是很恰当，因为上药当初并购中信，看中的就是北京区域的市场。
今天国家主席胡锦涛访问美国，与此同时，商务部组织了大型代表团，为此次国家元首访美做铺垫，兵马未动，商贸先行！今天抵达北卡的中国代表团由商业部副部长王超带队， 90 多位企业家跟随，其行业包括能源环保、机械电子、化工医药、银行投资、农副产品、日用品及原材料等。 北卡州政府高规格接待，由州长 Perdue 、北卡在华盛顿的一位参议员和一位众议员、美国商务部长助理以及北卡商务厅全体班子成员一起恭迎来自中国的官员和大款们。作为州长的顾问会成员我也被通知务必到场。与会期间，中美双方当场签署了 3 份合作协议，其中第一项是北京的轩辕投资公司与北卡的 Hamner Institute for Health Sciences 签署的 multi-million dollar 投资协议。去年年初我在国内时顺便参加过双方的接洽，看来这个项目历经一年的谈判，终于开花了。 北卡目前已经有收购了 IBM 北卡研发总部的联想集团，有收购了国际名牌家具企业的美克公司海外总部等一批中国知名企业了。午餐交流时有个企业家跟我说要买一所美国大学。我以为他说的是那种小型的本科 college ，结果人家认真地跟我说，收购对象必须是综合性大学，要有研究生院，要有医学院。我心里有点惊讶，这种项目操作起来需要巨大的人力物力，不是随便聊聊的话题，无法判断这个企业家是否想“玩真的”，也不知这种念头是否在国内投资界具有代表性－ 现在国内办大学拿个教育部的“准生证”都那么难，还要运行很多年才能在业内建立起品牌来，有这点功夫和资金的话不如到发达国家去收购一所较好品牌的大学来得更靠谱、更痛快一点！
今天一大早就看到一位朋友的电邮，告诉我这个消息。google了一下，没有找到新闻，药明康德的网站主页也没有找到相关资料，幸好看到查理河（aka: 查尔斯河）自己发布了，否则我还真不敢随便贴这个新闻。 3个月前收购的消息吸引了很多人的注意，毕竟药明康德是现在国内新药研发外包服务做得最好最大的公司。我也曾为此也写了篇短文 http://www.sciencenet.cn/m/user_content.aspx?id=316551 可是没有想到这么快就流产了。当然，这种事也是有发生，利益分配问题总是很难让所有的大股东们满意。不过，我怀疑还有不少买家会出手，现在也许是好时候。 参考： http://www.criver.com/en-US/NewsEvents/PressReleases/Pages/July29_2010.aspx CHARLES RIVER ANNOUNCES MUTUAL TERMINATION OF ACQUISITION AGREEMENT WITH WUXI PHARMATECH Board of Directors Approves $500 Million Stock Repurchase Plan Special Stockholder Meeting Canceled Second-Quarter Earnings Release and Conference Call Rescheduled WILMINGTON, MA, July 29, 2010 Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, today announced that it has mutually agreed with WuXi PharmaTech (Cayman) Inc. (NYSE: WX) to terminate their previously announced acquisition agreement. The Company also announced that its Board of Directors has authorized a new $500 million stock repurchase program. The termination agreement provides for Charles River to pay WuXi a $30 million breakup fee for full satisfaction of the parties obligations under the acquisition agreement and includes mutual releases of any claims and liabilities arising out of or relating to the acquisition agreement. As a result of the termination of the acquisition agreement, the special meeting of Charles River stockholders to be held on August 5, 2010 has been canceled. James C. Foster, Chairman, President and Chief Executive Officer said, We believed that this transaction, which would have created the premier early-stage contract research organization, would have resulted in long-term strategic benefits for our business and our shareholders. We also value our stockholders views and given their concerns about the proposed transaction, and our commitment not to proceed without their support, we have decided that terminating the transaction is the appropriate action to take. Although we are disappointed in the outcome of the proposed transaction, our overall strategy remains unchanged. We intend to be the premier early-stage CRO and will continue to build our early development capabilities specifically our discovery services in order to support our clients efforts across a broader portion of the drug development pipeline. We will enhance our portfolio of essential products and services, deepen our scientific expertise and maintain our standards of exceptional client service, all of which distinguish Charles River as an industry leader and make us the strategic partner of choice in early-stage drug development. The Boards action to authorize a new stock repurchase plan at this time reflects both its belief that our stock price is substantially undervalued and also its faith in Charles Rivers future prospects. Repurchasing our stock is another means of enhancing earnings growth and improving stockholder value, he concluded. Board Authorizes Stock Repurchase Plan Charles Rivers Board of Directors has authorized the repurchase of up to $500 million of its common stock. The Company is currently exploring alternatives for timely execution. The stock purchases may be made from time to time through a variety of methods, including open market repurchases such as block trades, 10b5-1 plans or otherwise in compliance with Rule 10b-18 of the federal securities laws and/or privately negotiated transactions. Funds for the repurchases are expected to come from cash on hand, cash generated by operations, our existing credit facilities or other financing. Charles River has previously repurchased approximately 11 million shares under its prior $600 million stock repurchase authorization, and as of July 15, 2010, had approximately 66.3 million shares of common stock outstanding. That authorization, under which there was a remaining balance of approximately $145 million, has been canceled. Repurchases may be commenced or suspended at any time or from time to time without prior notice, depending on our view of market conditions and other factors. There are currently no specific plans for the shares that may be purchased under the program. Earnings Release/Webcast Rescheduled Charles River has rescheduled its second-quarter 2010 earnings release to Monday, August 2, at 6:30 a.m. ET, with a live webcast to discuss matters relating to the press release beginning at 8:30 a.m. ET on the same day. To participate in the webcast, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of non-GAAP financial measures to comparable GAAP financial measures on the website. About Charles River Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our approximately 8,000 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com . Forward-Looking Statements This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as anticipate, believe, expect, will, may, estimate, plan, outlook, and project and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding changes in our expectations regarding stock repurchases; the future demand for drug discovery and development products and services (particularly in light of the challenging economic environment), including the outsourcing of these services and present spending trends by our customers; the development and performance of our services and products; market and industry conditions; and Charles Rivers future performance. Forward looking statements are based on Charles Rivers current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the ability to successfully integrate businesses we acquire; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our customers; the ability to convert backlog to sales; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 19, 2010, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law. ### Investor Contact: Susan E. Hardy Corporate Vice President, Investor Relations 781.222.6190 susan.hardy@crl.com Media Contact: Amy Cianciaruso Director, Public Relations 781.222.6168 amy.cianciaruso@crl.com
标签: 收购
